Jublia costs roughly $800 for a small 4-milliliter bottle, and a full course of treatment can run well over $1,600. That price tag for a topical nail fungus solution shocks most people, and several factors explain it: patent protection that has kept generics off the market, a specialized formulation that took years to develop, and limited competition in a niche treatment category.
What Jublia Actually Costs
At retail, a 4-milliliter bottle of Jublia runs about $806, while the 8-milliliter size costs around $1,605. Treatment for toenail fungus typically requires daily application for 48 weeks, meaning most people need multiple bottles over the course of a year. Without insurance, the total out-of-pocket cost can easily reach several thousand dollars for a single course of treatment.
Many insurance plans either don’t cover Jublia or place it on a high-cost specialty tier with significant copays. That leaves a large number of patients facing something close to full price.
Patent Protection Blocks Cheaper Versions
The biggest driver of Jublia’s price is the lack of generic competition. Since its FDA approval in 2014, Jublia has been protected by patents that prevent other manufacturers from producing lower-cost copies. That monopoly means the manufacturer, Bausch Health (formerly Valeant), has had no pressure to lower the price.
That may finally be changing. The FDA’s Orange Book shows a generic version of efinaconazole (Jublia’s active ingredient) from Alembic Pharmaceuticals received approval in February 2026. Once generics actually reach pharmacy shelves, prices typically drop significantly, often by 80% or more over time. But until generic supply is established and widely available, Jublia’s pricing will likely remain high.
A Formulation Designed to Penetrate Nail
Part of what you’re paying for is genuine innovation in drug delivery. Toenail fungus lives underneath and within the nail plate, which is a dense barrier made of keratin. Older topical treatments like ciclopirox nail lacquer struggled to get enough active drug through the nail to the infection site. Jublia was engineered with a low surface tension vehicle that helps the drug penetrate through the nail plate and spread into the space between the nail and the nail bed, where the fungus actually lives.
This formulation work is expensive to develop and patent, and it gives the manufacturer justification for premium pricing. It also contributes to Jublia’s better clinical results compared to older topicals.
It Works Better Than Other Topicals
Jublia’s price partly reflects the fact that it outperforms its competitors, though the numbers are still modest in absolute terms. In clinical trials, Jublia achieved complete cure rates of 15 to 18%, compared to 6.5 to 9% for tavaborole (brand name Kerydin) and 5.5 to 8.5% for ciclopirox. Its mycological cure rate, meaning the fungus was eliminated even if the nail hadn’t fully cleared, reached 53 to 55%, roughly double what ciclopirox achieved.
Those complete cure numbers may look low, but toenail fungus is notoriously stubborn to treat. Jublia’s performance actually rivals oral antifungal pills, which carry more systemic side effects like liver toxicity risk. Being the most effective topical option in a condition with few good alternatives gives the manufacturer pricing power that wouldn’t exist if the drug were only marginally better.
Limited Competition Keeps Prices High
The prescription topical toenail fungus market is small. Only three branded products have been widely available: Jublia, Kerydin (tavaborole), and the older ciclopirox lacquer. Ciclopirox does have generic versions available at much lower cost, but its cure rates are significantly worse. Kerydin sits in between on efficacy but carries a similarly high brand-name price.
With so few products competing for the same patients, there’s little incentive for any manufacturer to cut prices. Doctors who want to prescribe the most effective topical option really only have one choice, and that gives Jublia’s manufacturer leverage to maintain premium pricing.
Ways to Reduce the Cost
The manufacturer offers a patient assistance program through Bausch Health for people with no prescription drug coverage and a household income at or below 300% of the federal poverty level. If you qualify, this can substantially reduce or eliminate costs.
For those with insurance, the manufacturer has periodically offered savings cards or copay assistance programs that reduce the per-fill cost, though eligibility and savings amounts vary. Pharmacy discount platforms like GoodRx sometimes list lower cash prices at certain pharmacies, though Jublia still typically costs hundreds of dollars even with a coupon.
If cost is the primary barrier, it’s worth discussing alternatives with a prescriber. Generic ciclopirox is far cheaper, though less effective. Oral antifungal pills are another option with comparable cure rates to Jublia at a fraction of the cost, since generic oral treatments have been available for years. The tradeoff is a small risk of side effects that topical treatments avoid. Once generic efinaconazole reaches the market, patients will likely have access to the same formulation at a much lower price point.